Gustav Brismark

Before starting his own business in 2019, Mr Brismark had over 30 years of experience from Research, Development of Wireless cellular standards and FRAND licensing, at Ericsson.  He started his career as a research engineer and inventor, on algorithm research for 2G cellular standards (GSM, US-TDMA and Japanese PDC) and later for 3G WCDMA. In the late 1990’s he was responsible for Ericsson’s standardisation acitvities in Japan, at the time when 3GPP was formed, enabling one global standard development activity for 3G WCDMA, with the endorsement of regional standards bodies worldwide.  From 2004-2019, Mr Brismark was part of the management of Ericsson’s IPR Licensing business. As the VP of IPR Strategy from 2006, part of his responsibility was IPR Policy matters and participation in ETSI IPR Special Committee as well as the Ad Hoc Group on IPR in ITU.  He served as the Chief Intellectual Property Officer (CIPO) at Ericsson, 2016-2019. As the CIPO Mr. Brismark was responsible for Ericsson’s worldwide patent licensing business and patent development.

In 2019 Mr Brismark founded Kazehara AB, providing consultancy services in IPR strategy, IPR value-creation, FRAND-licensing and eco-system development.  Since 2019, Mr Brismark has also been serving as a patent licensing expert witness in several patent litigation processes.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent
Read More

Universities, Patents, and the Future of U.S. Competitiveness

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties
Read More

How Counterfeit Drugs Threaten U.S. Health and Innovation

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor
Read More